title: Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
abstract: Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib.
  
  
  
  We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherlands, for SLCO1B1, SLCO1B3, ABCC2, ABCG2, UGT1A1 and UGT1A9.
  
  
  
  The UGT1A1 (rs8175347) polymorphism was associated with hyperbilirubinemia and treatment interruption. Polymorphisms in SLCO1B1 (rs2306283, rs4149056) were associated with diarrhea and thrombocytopenia, respectively. None of the investigated polymorphisms was associated with overall or progression-free survival in hepatocellular cancer patients.
  
  
  
  Polymorphisms in SLCO1B1 and UGT1A1 are associated with several different sorafenib side effects.
authors.affiliation: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: Sander
authors.initials: S
authors.lastname: Bins
authors.affiliation: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: Anne
authors.initials: A
authors.lastname: Lenting
authors.affiliation: Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
authors.forename: Samira
authors.initials: S
authors.lastname: El Bouazzaoui
authors.affiliation: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: Leni
authors.initials: L
authors.lastname: van Doorn
authors.affiliation: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: Esther
authors.initials: E
authors.lastname: Oomen-de Hoop
authors.affiliation: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: Ferry Alm
authors.initials: FA
authors.lastname: Eskens
authors.affiliation: Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
authors.forename: Ron Hn
authors.initials: RH
authors.lastname: van Schaik
authors.affiliation: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: Ron Hj
authors.initials: RH
authors.lastname: Mathijssen
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D005838:Genotype; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality; D027381:Liver-Specific Organic Anion Transporter 1 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D000089762:Multidrug Resistance-Associated Protein 2; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000009:adverse effects*; D020641:Polymorphism, Single Nucleotide; D012189:Retrospective Studies; D000077157:Sorafenib; D000099148:UGT1A1 Enzyme
chemical_list: D000970:Antineoplastic Agents; D014453:Glucuronosyltransferase; D027381:Liver-Specific Organic Anion Transporter 1; D000089762:Multidrug Resistance-Associated Protein 2; D009536:Niacinamide; D010671:Phenylurea Compounds; D000077157:Sorafenib; D000099148:UGT1A1 Enzyme; C000715087:ABCC2 protein, human; C503999:SLCO1B1 protein, human
keywords: drug transporters; hepatocellular carcinoma; pharmacogenetics; renal cell cancer; sorafenib; toxicity